Anbio Biotechnology (NASDAQ:NNNN) Sees Large Decrease in Short Interest

Anbio Biotechnology (NASDAQ:NNNN) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 31,124 shares, a drop of 42.4% from the September 30th total of 54,022 shares. Based on an average daily volume of 46,624 shares, the short-interest ratio is currently 0.7 days. Currently, 0.0% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Hold rating. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Anbio Biotechnology Price Performance

Shares of NASDAQ NNNN traded down $0.36 on Friday, reaching $3.36. 39,020 shares of the company’s stock traded hands, compared to its average volume of 56,927. Anbio Biotechnology has a 12 month low of $3.09 and a 12 month high of $44.73. The business’s 50 day simple moving average is $5.47 and its two-hundred day simple moving average is $16.73.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.